# Neuron23

**Canonical:** https://apis.io/providers/neuron23/  
**Website:** https://neuron23.com/  
**APIs profiled:** 0

Neuron23 is a clinical-stage precision-medicine biotechnology company developing genetically targeted small-molecule therapies for neurological and immunological diseases, with a lead precision-medicine program focused on Parkinson's disease. It combines machine-learning-driven genetic biomarker discovery with drug development to match patients to the therapies most likely to help them. Surfaced in the API Evangelist network as a portfolio company of SoftBank Vision Fund, Neuron23 is a therapeutics company that publishes no public API, developer portal, SDK, or technical documentation surface as of this enrichment pass.

## Kin Score — 3.3 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 3.3).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Neuron23 Domain Security** — TLSv1.3 · HSTS

## Tags

Company, Health Tech, Biotechnology, Precision Medicine, Neuroscience, Pharmaceuticals, Drug Discovery, Parkinson's Disease

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/neuron23/). Scores are computed from the provider's own public artifacts under a published rubric.